HCV Inhibitor

HCV Inhibitors (357):

Cat. No.	Product Name	Effect	Purity

HY-13740

Resiquimod	Inhibitor	99.95%
Resiquimod is a Toll-like receptor 7 and 8 (TLR7/TLR8) agonist that induces the upregulation of cytokines such as TNF-α, IL-6 and IFN-α.

HY-B0434

Ribavirin	Inhibitor	99.96%
Ribavirin (ICN-1229) is an antiviral agent against a broad spectrum of viruses including HCV, HIVl, and RSV. Ribavirin also has anti-orthopoxvirus and anti-variola activities.

HY-107433

U18666A	Inhibitor	99.92%
U18666A, an intra-cellular cholesterol transport inhibitor, inhibits replication of Ebola virus, dengue virus, and human hepatitis C virus.

HY-B0568

Deferiprone	Inhibitor	99.98%
Deferiprone is a potent, orally active, brain-penetrant, cell-penetrant, skin-permeable, free iron chelating agent. Deferiprone inhibits the proliferation and migration, and stimulates apoptosis in tumor cell. Deferiprone can inhibit KDM. Deferiprone has antianemic, neuroprotective, anti-inflammatory, antioxidant, and antidotal activity. Deferiprone can be used in cancer, cardiovascular disease, infection, inflammation, and neurological disease study.

HY-N0003

Honokiol	Inhibitor	99.90%
Honokiol is a bioactive, biphenolic phytochemical that possesses potent antioxidative, anti-inflammatory, antiangiogenic, and anticancer activities by targeting a variety of signaling molecules. It inhibits the activation of Akt. Honokiol can readily cross the blood brain barrier.

HY-108764B

Mipomersen sodium scrambled negative control	Inhibitor	98.20%
Mipomersen sodium scrambled negative control is the sequence scrambled negative control of Mipomersen sodium.

HY-115516

BI-1388	Inhibitor
BI-1388 is a macrocyclic acylsulfonamide-based HCV NS3-4A protease inhibitor. BI-1388 inhibits clinically relevant drug-resistant mutant strains (KRAS^D168V gt 1b and KRAS^R155K gt 1a) and exhibits high liver distribution. BI-1388 is applicable for the research of HCV infection.

HY-186153

Antiviral agent 82	Inhibitor
Antiviral agent 82 (example 1) is an anti-HCV agent. Antiviral agent 82 can be used to prevent infection with flaviviruses, particularly hepatitis C virus.

HY-N6798

Myriocin	Inhibitor	99.80%
Myriocin (Thermozymocidin), a fungal metabolite could be isolated from Myriococcum albomyces, Isaria sinclairi and Mycelia sterilia, is a potent inhibitor of serine-palmitoyl-transferase (SPT) and a key enzyme in de novo synthesis of sphingolipids. Myriocin suppresses replication of both the subgenomic HCV-1b replicon and the JFH-1 strain of genotype 2a infectious HCV, with an IC₅₀ of 3.5 μg/mL for inhibiting HCV infection.

HY-B0094

Artemisinin	Inhibitor	98.0%
Artemisinin (Qinghaosu), a sesquiterpene lactone, is an anti-malarial agent isolated from the aerial parts of Artemisia annua L. plants. Artemisinin inhibits AKT signaling pathway by decreasing pAKT in a dose-dependent manner. Artemisinin reduces cancer cell proliferation, migration, invasion, tumorigenesis and metastasis and has neuroprotective effects.

HY-13524

AG-1478	Inhibitor	99.57%
AG-1478 (Tyrphostin AG-1478) is a selective EGFR tyrosine kinase inhibitor with IC₅₀ of 3 nM. AG-1478 has antiviral effects against HCV and encephalomyocarditis virus (EMCV).

HY-14434

Asunaprevir	Inhibitor	99.84%
Asunaprevir (BMS-650032) is a potent and orally bioavailable hepatitis C virus (HCV) NS3 protease inhibitor, with IC₅₀ of 0.2 nM-3.5 nM. Asunaprevir inhibits SARS-CoV-2 3CL^pro activity.

HY-116767

BLT-1	Inhibitor	99.93%
BLT-1, a thiosemicarbazone copper chelator, is a selective scavenger receptor B, type 1 (SR-BI) inhibitor. BLT-1 inhibits the transfer of lipids between high-density lipoproteins (HDL) and cells mediated by SR-BI. BLT-1 is a potent HCV entry inhibitor.

HY-15298

Grazoprevir	Inhibitor	99.90%
Grazoprevir (MK-5172) is a selective inhibitor of Hepatitis C virus NS3/4a protease with broad activity across genotypes and resistant variants, with K_is of 0.01 nM (gt1b), 0.01 nM (gt1a), 0.08 nM (gt2a), 0.15 nM (gt2b), 0.90 nM (gt3a), respectively. Grazoprevir inhibits SARS-CoV-2 3CL^pro activity.

HY-15005

Sofosbuvir	Inhibitor	99.99%
Sofosbuvir (GS-7977) is an HCV RNA replication inhibitor with an EC₅₀ of 92 nM.

HY-10241

Simeprevir	Inhibitor	98.79%
Simeprevir (TMC435; TMC435350) is an oral, potent and highly specific hepatitis C virus (HCV) NS3/4A protease inhibitor with a K_i of 0.36 nM. Simeprevir inhibits HCV replication with an EC₅₀ of 7.8 nM. Simeprevir also potently suppresses SARS-CoV-2 replication and synergizes with Remdesivir. Simeprevir inhibits the main protease (M^pro) and the RNA-dependent RNA polymerase (RdRp) of SARS-CoV-2, and also modulates host immune responses.

HY-125033

EIDD-1931	Inhibitor	99.98%
EIDD-1931 (Beta-d-N4-hydroxycytidine; NHC) is a novel nucleoside analog and behaves as a potent anti-virus agent. EIDD-1931 effectively inhibits the replication activity of venezuelan equine encephalitis virus (VEEV), Chikungunya virus (CHIKV) and hepatitis C virus (HCV).

HY-W063968

RO8191	Inhibitor	≥99.0%
RO8191 (CDM-3008), an imidazonaphthyridine compound, is an orally active and potent interferon (IFN) receptor agonist. RO8191 directly binds to IFNα/β receptor 2 (IFNAR2) and activates IFN-stimulated genes (ISGs) expression and JAK/STAT phosphorylation. RO8191 shows antiviral activity against both HCV and EMCV with an IC₅₀ of 200 nM for HCV replicon. RO8191 is a cccDNA modulator (CDM) through interferon-like activity and has anti-HBV activity.

HY-P0025

NIM811	Inhibitor	99.87%
NIM811 ((Melle-4)cyclosporin; SDZ NIM811) is an orally bioavailable mitochondrial permeability transition and cyclophilin dual inhibitor, which exhibits potent in vitro activity against hepatitis C virus (HCV) .

HY-108764

Mipomersen sodium	Inhibitor
Mipomersen sodium (ISIS 301012) is an antisense oligonucleotide inhibitor of apolipoprotein B (apoB). Mipomersen has anti-HCV effect and reduces the infectivity of the HCV. Mipomersen sodium can be used for the research of homozygous familial hypercholesterolemia (HoFH).

Name
Email *

	Sorry, but the email address you supplied was invalid.